{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:15:03Z","timestamp":1790792103568,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,1,11]],"date-time":"2016-01-11T00:00:00Z","timestamp":1452470400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s10072-015-2471-z","type":"journal-article","created":{"date-parts":[[2016,1,11]],"date-time":"2016-01-11T09:21:57Z","timestamp":1452504117000},"page":"743-747","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["The relation of serum uric acid levels with l-Dopa treatment and progression in patients with Parkinson\u2019s disease"],"prefix":"10.1007","volume":"37","author":[{"given":"Eugeniu","family":"Vieru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayhan","family":"K\u00f6ksal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belgin","family":"Mutluay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayten Ceyhan","family":"Dirican","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yavuz","family":"Altunkaynak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevim","family":"Baybas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,11]]},"reference":[{"issue":"9423","key":"2471_CR1","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/S0140-6736(04)16305-8","volume":"363","author":"A Samii","year":"2004","unstructured":"Samii A, Nutt JG, Ransom BR (2004) Parkinson\u2019s disease. The Lancet 363(9423):1783\u20131793","journal-title":"The Lancet"},{"issue":"305","key":"2471_CR2","first-page":"205","volume":"7","author":"MP Brug Van der","year":"2015","unstructured":"Van der Brug MP, Singleton A, Gasser T, Lewis PA (2015) Parkinson\u2019s disease: From human genetics to clinical trials. SciTransl Med 7(305):205","journal-title":"SciTransl Med"},{"issue":"5","key":"2471_CR3","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2217\/bmm.10.94","volume":"4","author":"S Cipriani","year":"2010","unstructured":"Cipriani S, Chen X, Schwarzschild MA (2010) Urate: a novel biomarker of Parkinson\u2019s disease risk, diagnosis and prognosis. Biomarkers in Medicine 4(5):701\u2013712","journal-title":"Biomarkers in Medicine"},{"key":"2471_CR4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1749-6632.2002.tb04072.x","volume":"962","author":"M Whiteman","year":"2002","unstructured":"Whiteman M, Ketsawatsakul U, Halliwell B (2002) A reassessment of the peroxynitrite scavenging activity of uric acid. Ann N Y Acad Sci 962:242\u2013259","journal-title":"Ann N Y Acad Sci"},{"issue":"10","key":"2471_CR5","first-page":"1864","volume":"26","author":"MA Schwarzschild","year":"2011","unstructured":"Schwarzschild MA, Marek K, Eberly S, Oakes D, Shoulson I, Jennings D, Seibyl J, Ascherio A, Parkinson Study Group PRECEPT Investigators (2011) Serum urate and probability of dopaminergic deficit in early \u2018Parkinson disease\u2019. MovDisord 26(10):1864\u20131868","journal-title":"MovDisord"},{"issue":"12","key":"2471_CR6","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/archneurol.2009.247","volume":"66","author":"A Ascherio","year":"2009","unstructured":"Ascherio A, LeWitt PA, Xu K et al (2009) Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 66(12):1460\u20131468","journal-title":"Arch Neurol"},{"key":"2471_CR7","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.neulet.2012.02.077","volume":"514","author":"HN Zhang","year":"2012","unstructured":"Zhang HN, Guo JF, He D et al (2012) Lower serum UA levels in Parkinson\u2019s disease patients in the Chinese population. Neurosci Lett 514:152\u2013155","journal-title":"Neurosci Lett"},{"issue":"5","key":"2471_CR8","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/oxfordjournals.aje.a008954","volume":"144","author":"JW Davis","year":"1996","unstructured":"Davis JW, Grandinetti A, Waslien CI, Ross GW, White LR, Morens DM (1996) Observations on serum uric acid levels and the risk of idiopathic Parkinson\u2019s disease. Am J Epidemiol 144(5):480\u2013484","journal-title":"Am J Epidemiol"},{"issue":"9","key":"2471_CR9","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.clineuro.2009.06.012","volume":"111","author":"E Andreadou","year":"2009","unstructured":"Andreadou E, Nikolaou C, Gournaras F et al (2009) Serum uric acid levels in patients with Parkinson\u2019s disease: their relationship to treatment and disease duration. Clinical Neurology and Neurosurgery 111(9):724\u2013728","journal-title":"Clinical Neurology and Neurosurgery"},{"issue":"4","key":"2471_CR10","first-page":"583","volume":"125","author":"CC Sun","year":"2012","unstructured":"Sun CC, Luo FF, Wei L, Lei M, Li GF, Liu ZL, LE WD, Xu PY (2012) Association of serum uric acid levels with the progression of Parkinson\u2019s disease in Chinese patients. Chinese Med J 125(4):583\u2013587","journal-title":"Chinese Med J"},{"key":"2471_CR11","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.mehy.2009.04.030","volume":"73","author":"AH Bucay","year":"2009","unstructured":"Bucay AH (2009) A new hypothesis about the role of uric acid as a neurotransmitter. Med Hypotheses 73:854\u2013865","journal-title":"Med Hypotheses"},{"key":"2471_CR12","doi-asserted-by":"crossref","first-page":"e003620","DOI":"10.1136\/bmjopen-2013-003620","volume":"3","author":"L Shen","year":"2013","unstructured":"Shen L, Ji HF (2013) Low uric acid levels in patients with Parkinson\u2019s disease: evidence from meta-analysis. BMJ Open 3:e003620. doi: 10.1136\/bmjopen-2013-003620","journal-title":"BMJ Open"},{"key":"2471_CR13","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/mds.21502","volume":"22","author":"T Annanmaki","year":"2007","unstructured":"Annanmaki T, Muuronen A, Murros K (2007) Low plasma uric acid level in Parkinson\u2019s disease. Mov Disord 22:1133\u20131137","journal-title":"Mov Disord"},{"key":"2471_CR14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0022-3565(25)33291-X","volume":"223","author":"DW Bierer","year":"1982","unstructured":"Bierer DW, Quebbemann AJ (1982) Effect of L-Dopa on renal handling of uric acid. J Pharmacol Exp Ther 223:55\u201359","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"2471_CR15","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/archneur.65.6.698","volume":"65","author":"M Schiess","year":"2008","unstructured":"Schiess M, Oh I (2008) Serum uric acid and clinical progression in Parkinson disease: potential biomarker for nigrostriatal failure. Arch Neurol 65(6):698\u2013699","journal-title":"Arch Neurol"},{"issue":"2","key":"2471_CR16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/ane.12295","volume":"131","author":"M Moccia","year":"2015","unstructured":"Moccia M, Pappat\u00e0 S, Erro R et al (2015) Uric acid relates to dopamine transporter availability in Parkinson\u2019s disease. Acta Neurol Scand. 131(2):127\u2013131","journal-title":"Acta Neurol Scand."},{"issue":"7","key":"2471_CR17","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.parkreldis.2014.03.016","volume":"20","author":"M Moccia","year":"2014","unstructured":"Moccia M, Picillo M, Erro R et al (2014) Is serum uric acid related to non-motor symptoms in de-novo Parkinson\u2019s disease patients? Parkinsonism Relat Disord. 20(7):772\u2013775","journal-title":"Parkinsonism Relat Disord."},{"issue":"1","key":"2471_CR18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/ene.12533","volume":"22","author":"M Moccia","year":"2015","unstructured":"Moccia M, Picillo M, Erro R et al (2015) Presence and progression of non-motor symptoms in relation to uric acid in de novo Parkinson\u2019s disease. Eur J Neurol. 22(1):93\u201398","journal-title":"Eur J Neurol."},{"issue":"4","key":"2471_CR19","first-page":"419","volume":"33","author":"WH Church","year":"1994","unstructured":"Church WH, Ward VL (1994) Uric acid is reduced in the substantia nigra in Parkinson\u2019s disease: effect on dopamine oxidation. Brain ResBull. 33(4):419\u2013425","journal-title":"Brain ResBull."},{"issue":"3","key":"2471_CR20","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s12031-010-9409-y","volume":"43","author":"MF Facheris","year":"2011","unstructured":"Facheris MF, Hicks AA, Minelli C et al (2011) Variation in the Uric Acid Transporter Gene SLC2A9 and Its Association with AAO of Parkinson\u2019s Disease. J Mol Neurosci 43(3):246\u2013250","journal-title":"J Mol Neurosci"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-015-2471-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-015-2471-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-015-2471-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T03:00:32Z","timestamp":1748746832000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-015-2471-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,11]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["2471"],"URL":"https:\/\/doi.org\/10.1007\/s10072-015-2471-z","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,11]]}}}